Heart failure (HF) is a progressive disease characterized by variable durations of
symptomatic stability often punctuated by episodes of worsening despite continued therapy …

Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Myosin modulators are a novel class of pharmaceutical agents that are being developed to
treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to …

Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Worsening heart failure (WHF) is a severe and dynamic condition characterized by
significant clinical and hemodynamic deterioration. It is characterized by worsening HF …

Hypertensive heart disease constitutes functional and structural dysfunction and
pathogenesis occurring primarily in the left ventricle, the left atrium and the coronary arteries …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …

Aim Persistent symptoms despite guideline‐directed medical therapy (GDMT) and poor
tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced …

Aims The Heart Failure Association of the European Society of Cardiology (HFA‐ESC)
proposed a definition of advanced heart failure (HF) that has not been validated, yet. We …